Company intelligence / Profile preview

Tissue Regenix Group

Leeds, England, United Kingdom

Ownership: Private
Employees: ~100
Development stage: Other

Overview

Tissue Regenix's products such as DermaPure (using dCELL Technology) and other allograft matrices are commercially available and supported by distribution agreements, US reimbursement, and increasing sales. The focus is on differentiated clinical outcomes in wound healing and tissue repair

Therapeutic areas: OtherDermatology
Modalities: DeviceBiologicAllograft
Industry: Biotech

Partnerships

Arthrex, Inc. (distribution)ARMS Medical (distribution for DermaPure)

Beyond the preview

Go deeper on Tissue Regenix Group.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tissue Regenix Group.

Explore the full profile